METHODS
One hundred and four patients with gastric adenocarcinoma
who received adjuvant CRT were evaluated retrospectively.
RESULTS
The median overall survival time was 28.30 months, and 3-year
and 5-year median survival rates were 47.6% and 33.6%, respectively.
The median disease-free survival, however, was 23.97
months, and 3-year and 5-year disease-free survival rates were
38.1% and 26.2%, respectively. Regarding with the evaluation
of various prognostic factors, the number of involved lymph
nodes (LN) and positive surgical margins for overall survival;
the performance status for disease-free survival; and the rate of
LN involvement along with the number of chemotherapy treatments
≥3 for both disease-free survival and overall survival were
determined statistically significant via univariate analysis. In
multivariate analysis, positive surgical margins, the number of
involved LNs and the rate of LN involvement were defined statistically
significant for overall survival, whereas no parameter
was determined statistically significant for disease-free survival.
CONCLUSION
An improvement in overall survival and disease-free survival
has been achieved with the treatment of adjuvant CRT in patients
with gastric cancers.
Keywords: Chemoradiotherapy; gastric cancer; prognostic factors; survival
